The effect of chronic methylphenidate administration on presynaptic dopaminergic parameters in a rat model for ADHD

European Neuropsychopharmacology

Volumn 20, Issue 10, 2010, Pages 714-720

  Simchon, Y ^a   Weizman, A ^a,b   Rehavi, M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

Attention deficit hyperactivity disorder (ADHD); Dopamine transporter (DAT); Methylphenidate (MPH); Spontaneous hypertensive rats (SHR); Vesicular monoamine transporter 2 (VMAT2); Wistar Kyoto rats (WKY)

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; METHYLPHENIDATE; VESICULAR MONOAMINE TRANSPORTER 2;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DRUG EFFECT; MALE; MORNING DOSAGE; NONHUMAN; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BINDING SITES; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; METHYLPHENIDATE; PIPERAZINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, DOPAMINE; SYNAPTOSOMES; TETRABENAZINE; TIME FACTORS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 77956169584     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.04.007     Document Type: Article

References (30)

1. Arnsten A.F. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 2006, 31(11):2376-2383.
2. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005, 57(11):1215-1220.
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
4. Coyle J.T., Snyder S.H. Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. J Pharmacol Exp Ther 1969, 170(2):221-231.
5. Curatolo P., Paloscia C., D'Agati E., Moavero R., Pasini A. The neurobiology of attention deficit/hyperactivity disorder. Eur J Paediatr Neurol 2009, 13(4):299-304.
6. Fleckenstein A.E., Volz T.J., Hanson G.R. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 2009, 56(Suppl 1):133-138.
7. Gordon I., Weizman R., Rosenne E., Rehavi M. Developmental and age-related alterations in rat brain presynaptic dopaminergic mechanisms. Brain Res Dev Brain Res 1995, 85(2):225-228.
8. Gordon I., Weizman R., Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 1996, 298(1):27-30.
9. Goto Y., Otani S., Grace A.A. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 2007, 53(5):583-587.
10. Janowsky A., Berger P., Vocci F., Labarca R., Skolnick P., Paul S.M. Characterization of sodium-dependent [3H]GBR-12935 binding in brain: a radioligand for selective labelling of the dopamine transport complex. J Neurochem 1986, 46(4):1272-1276.
11. Kantak K.M., Singh T., Kerstetter K.A., Dembro K.A., Mutebi M.M., Harvey R.C., et al. Advancing the spontaneous hypertensive rat model of attention deficit/hyperactivity disorder. Behav Neurosci 2008, 122(2):340-357.
12. Leo D., Sorrentino E., Volpicelli F., Eyman M., Greco D., Viggiano D., et al. Altered midbrain dopaminergic neurotransmission during development in an animal model of ADHD. Neurosci Biobehav Rev 2003, 27(7):661-669.
13. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193(1):265-275.
14. Madras B.K., Miller G.M., Fischman A.J. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57(11):1397-1409.
15. Moll G.H., Hause S., Ruther E., Rothenberger A., Huether G. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol 2001, 11(1):15-24.
16. Pliszka S.R. The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57(11):1385-1390.
17. Russell V., de Villiers A., Sagvolden T., Lamm M., Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Brain Res 1995, 676(2):343-351.
18. Russell V., de Villiers A., Sagvolden T., Lamm M., Taljaard J. Differences between electrically-, ritalin- and d-amphetamine-stimulated release of [3H]dopamine from brain slices suggest impaired vesicular storage of dopamine in an animal model of attention-deficit hyperactivity disorder. Behav Brain Res 1998, 94(1):163-171.
19. Russell V.A. Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Behav Brain Res 2002, 130(1-2):191-196.
20. Russell V.A., de Villiers A.S., Sagvolden T., Lamm M.C., Taljaard J.J. Methylphenidate affects striatal dopamine differently in an animal model for attention-deficit/hyperactivity disorder - the spontaneously hypertensive rat. Brain Res Bull 2000, 53(2):187-192.
21. Sagvolden T., Russell V.A., Aase H., Johansen E.B., Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57(11):1239-1247.
22. Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J Neurosci 2002, 22(19):8705-8710.
23. Scherman D. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J Neurochem 1986, 47(2):331-339.
24. Seeman P., Madras B.K. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 1998, 3(5):386-396.
25. Volz T.J., Bjorklund N.L., Schenk J.O. Methylphenidate analogs with behavioral differences interact differently with arginine residues on the dopamine transporter in rat striatum. Synapse 2005, 57(3):175-178.
26. Volz T.J., Farnsworth S.J., Hanson G.R., Fleckenstein A.E. Methylphenidate-induced alterations in synaptic vesicle trafficking and activity. Ann N Y Acad Sci 2008, 1139:285-290.
27. Volz T.J., Farnsworth S.J., King J.L., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles. J Pharmacol Exp Ther 2007, 323(2):738-745.
28. Watanabe Y., Fujita M., Ito Y., Okada T., Kusuoka H., Nishimura T. Brain dopamine transporter in spontaneously hypertensive rats. J Nucl Med 1997, 38(3):470-474.
29. Wilens T.E. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008, 28(3 Suppl 2):S46-53.
30. Yang P.B., Swann A.C., Dafny N. Acute and chronic methylphenidate dose-response assessment on three adolescent male rat strains. Brain Res Bull 2006, 71(1-3):301-310.